Risk of death after paclitaxel exposure during femoropopliteal artery Angioplasty - narrative review

Detalhes bibliográficos
Autor(a) principal: Ribeiro,Tiago F.
Data de Publicação: 2021
Outros Autores: Ferreira,Rita Soares, Cardoso,Joana, Figueiredo,Adriana, Fidalgo,Helena, Gonçalves,Frederico Bastos, Ferreira,Maria Emília
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://scielo.pt/scielo.php?script=sci_arttext&pid=S1646-706X2021000400313
Resumo: Abstract Paclitaxel molecule has been on the market since 1991 and is indicated for the treatment of multiple neoplasms. Since 2012 has been used in endovascular devices for the treatment of peripheral artery disease and have become a mainstay in the treatment of symptomatic femoro-popliteal lesions, in particular for preventing arterial restenosis. They have a proven benefit in patency and freedom-from re-intervention up to 5 years. A recent meta-analysis of RCT showed an increased late-mortality rate, however, real-life cohorts analyses presents contradictory results. RCT meta-analysis is comprised mainly by claudicants, and CLTI patients are underrepresented. Further studies are needed to clarify this matter, in particular with a higher percentage of CLTI presentation. For now, patients should be advised about risks and benefits of paclitaxel exposure and a shared decision-making process should be followed.
id RCAP_61051e25064866b047d77094844f4818
oai_identifier_str oai:scielo:S1646-706X2021000400313
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Risk of death after paclitaxel exposure during femoropopliteal artery Angioplasty - narrative reviewPeripheral Artery DiseaseEndovascular TherapyPaclitaxel Coated DevicesAbstract Paclitaxel molecule has been on the market since 1991 and is indicated for the treatment of multiple neoplasms. Since 2012 has been used in endovascular devices for the treatment of peripheral artery disease and have become a mainstay in the treatment of symptomatic femoro-popliteal lesions, in particular for preventing arterial restenosis. They have a proven benefit in patency and freedom-from re-intervention up to 5 years. A recent meta-analysis of RCT showed an increased late-mortality rate, however, real-life cohorts analyses presents contradictory results. RCT meta-analysis is comprised mainly by claudicants, and CLTI patients are underrepresented. Further studies are needed to clarify this matter, in particular with a higher percentage of CLTI presentation. For now, patients should be advised about risks and benefits of paclitaxel exposure and a shared decision-making process should be followed.Sociedade Portuguesa de Angiologia e Cirurgia Vascular2021-12-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S1646-706X2021000400313Angiologia e Cirurgia Vascular v.17 n.4 2021reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://scielo.pt/scielo.php?script=sci_arttext&pid=S1646-706X2021000400313Ribeiro,Tiago F.Ferreira,Rita SoaresCardoso,JoanaFigueiredo,AdrianaFidalgo,HelenaGonçalves,Frederico BastosFerreira,Maria Emíliainfo:eu-repo/semantics/openAccess2024-02-06T17:23:04Zoai:scielo:S1646-706X2021000400313Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T02:29:30.156010Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Risk of death after paclitaxel exposure during femoropopliteal artery Angioplasty - narrative review
title Risk of death after paclitaxel exposure during femoropopliteal artery Angioplasty - narrative review
spellingShingle Risk of death after paclitaxel exposure during femoropopliteal artery Angioplasty - narrative review
Ribeiro,Tiago F.
Peripheral Artery Disease
Endovascular Therapy
Paclitaxel Coated Devices
title_short Risk of death after paclitaxel exposure during femoropopliteal artery Angioplasty - narrative review
title_full Risk of death after paclitaxel exposure during femoropopliteal artery Angioplasty - narrative review
title_fullStr Risk of death after paclitaxel exposure during femoropopliteal artery Angioplasty - narrative review
title_full_unstemmed Risk of death after paclitaxel exposure during femoropopliteal artery Angioplasty - narrative review
title_sort Risk of death after paclitaxel exposure during femoropopliteal artery Angioplasty - narrative review
author Ribeiro,Tiago F.
author_facet Ribeiro,Tiago F.
Ferreira,Rita Soares
Cardoso,Joana
Figueiredo,Adriana
Fidalgo,Helena
Gonçalves,Frederico Bastos
Ferreira,Maria Emília
author_role author
author2 Ferreira,Rita Soares
Cardoso,Joana
Figueiredo,Adriana
Fidalgo,Helena
Gonçalves,Frederico Bastos
Ferreira,Maria Emília
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Ribeiro,Tiago F.
Ferreira,Rita Soares
Cardoso,Joana
Figueiredo,Adriana
Fidalgo,Helena
Gonçalves,Frederico Bastos
Ferreira,Maria Emília
dc.subject.por.fl_str_mv Peripheral Artery Disease
Endovascular Therapy
Paclitaxel Coated Devices
topic Peripheral Artery Disease
Endovascular Therapy
Paclitaxel Coated Devices
description Abstract Paclitaxel molecule has been on the market since 1991 and is indicated for the treatment of multiple neoplasms. Since 2012 has been used in endovascular devices for the treatment of peripheral artery disease and have become a mainstay in the treatment of symptomatic femoro-popliteal lesions, in particular for preventing arterial restenosis. They have a proven benefit in patency and freedom-from re-intervention up to 5 years. A recent meta-analysis of RCT showed an increased late-mortality rate, however, real-life cohorts analyses presents contradictory results. RCT meta-analysis is comprised mainly by claudicants, and CLTI patients are underrepresented. Further studies are needed to clarify this matter, in particular with a higher percentage of CLTI presentation. For now, patients should be advised about risks and benefits of paclitaxel exposure and a shared decision-making process should be followed.
publishDate 2021
dc.date.none.fl_str_mv 2021-12-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S1646-706X2021000400313
url http://scielo.pt/scielo.php?script=sci_arttext&pid=S1646-706X2021000400313
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S1646-706X2021000400313
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Angiologia e Cirurgia Vascular
publisher.none.fl_str_mv Sociedade Portuguesa de Angiologia e Cirurgia Vascular
dc.source.none.fl_str_mv Angiologia e Cirurgia Vascular v.17 n.4 2021
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799137362276515840

Registros relacionados